Abstract

Modern Applications in Pharmacy & Pharmacology Cyclin Dependent Kinases: Old Target with New Challenges for Anti-Cancer Drugs Mangi Lal Choudhary1, SS Sisodiya1, Neeraj Kumar2 and Shashank Shekhar Mishra2* 1Department of Pharmacology, Bhupal Nobles' College of Pharmacy, India 2Department of Pharmaceutical Chemistry, Geetanjali Institute of Pharmacy, India *Corresponding author: Shashank Shekhar Mishra, Assistant Professor, Geetanjali Institute of Pharmacy, Geetanjali University, Udaipur, Rajasthan, India Submission: January 20, 2018; Published: February 07, 2018 DOI: 10.31031/MAPP.2018.01.000513 ISSN 2637-7756Volume1 Issue3

Highlights

  • Cell cycle progression is governed by cyclin dependent kinases that are activated by cyclin binding and inhibited by the cdk inhibitors

  • Cyclin-dependent kinases are a family of serine or threonine protein kinases; Cyclic dependent kinases (CDKs), MAPKs, GSKs and CLKs

  • CDK4/cyclin D, CDK6/cyclin D and CDK2/cyclin E facilitate the G1-S phase transition by sequentially pRb, while CDK1/cyclin A, CDK2/cyclin A and CDK1/cyclin B are essential for S-phase progression and G2-M transition, respectively

Read more

Summary

Introduction

Cell cycle progression is governed by cyclin dependent kinases (cdks) that are activated by cyclin binding and inhibited by the cdk inhibitors. Four are directly involved in cell cycle control and regulate, namely CDK1, CDK2, CDK4 and CDK6. CDK7 and CDK9 are involved in cell growth and involved in the control of CDK activity. INK4 gene family codes a p16INK4a, p15INK4b, p18INK4c, and p19INK4d; all INK4 gens are bind to CDK4 and CDK6 and inhibit the activity of kinase by interfering on their confederation with D-type cyclins. CDKs are control the cell cycle in which CDK1 to CDK6, while CDK8, CDK9, CDK12 and CDK19 are linked to regulation of transcription [2]. CDK7 and CDK20 act in cell cycle control and transcription processes [3]

Cell cycle progression regulators
Mod Appl Pharm Pharmacol
Future Perspective and Conclusion
For possible submission use the below is the URL Submit Article
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.